Literature DB >> 32179200

The dual role of mir-146a in metastasis and disease progression.

Alipour Shahriar1, Gholizadeh Ghaleh-Aziz Shiva2, Babaei Ghader2, Jeddi Farhad3, Amjadi Hosein4, Haji Parsa5.   

Abstract

OBJECTIVE: MicroRNAs are ribonucleic acids that are single-stranded and endogenous non-coding acids that regulate gene expression in later stages of the translation process by binding to genomic regulatory sites. miR146a is mostly involved in the regulation of inflammatory systems and another process that role in the innate immune system. In the present review, we have focused on the recent acquisitions about the main role played by mir146a in the control of the immune system and tumorigenesis. The main purpose of this review article is to systematically investigate the mir146a and its role in regulating signaling pathways involved in cancer and the immune system as well as its involved therapeutic methods.
METHODS: Systematic search of MEDLINE, Web of Science and Cochrane Library was conducted for all comparative studies from 2000 to 2019 with the limitations of the English language.
RESULTS: For a notable period of time, researchers have mainly focused on the therapeutic mechanisms of mir146a involved in the modulation of inflammatory and anti-inflammatory genes. We found that levels of mir146a expression were associated with cancer cell metastasis as a dual role (Inhibitory and stimulatory roles). The results of various studies also showed that this microRNA has a therapeutic role through its effects on other gene expressions such as NF-kB, SIRT1, TNF- α and IL-1β and leads to disease control.
CONCLUSION: Knowledge about alterations in mir146a regulation will give a better understanding of the molecular basis for various chronic inflammatory diseases and cancers.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Cancer; Immune system; Metastasis; microRNAs; mir146a

Mesh:

Substances:

Year:  2020        PMID: 32179200     DOI: 10.1016/j.biopha.2020.110099

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  10 in total

Review 1.  Clinico-Pathological Importance of miR-146a in Lung Cancer.

Authors:  Javaid Ahmad Wani; Sabhiya Majid; Andleeb Khan; Azher Arafah; Ajaz Ahmad; Basit Latief Jan; Naveed Nazir Shah; Mohsin Kazi; Muneeb U Rehman
Journal:  Diagnostics (Basel)       Date:  2021-02-10

2.  MiRNA-218 Is Frequently Downregulated in Malignant Breast Tumors: A Footprint of Epstein-Barr Virus Infection.

Authors:  Javad Charostad; Mohsen Nakhaei; Azarakhsh Azaran; Gholam Abbas Kaydani; Akram Astani; Azim Motamedfar; Manoochehr Makvandi
Journal:  Iran J Pathol       Date:  2021-07-06

Review 3.  The role of microRNAs in COVID-19 with a focus on miR-200c.

Authors:  Hadi Sodagar; Shahriar Alipour; Sepideh Hassani; Shiva Gholizadeh-Ghaleh Aziz; Mohammad Hasan Khadem Ansari; Rahim Asghari
Journal:  J Circ Biomark       Date:  2022-03-21

4.  MicroRNA-146a promotes proliferation, migration, and invasion of HepG2 via regulating FLAP.

Authors:  Huihui Wang; Shubing Zhang; Tao Li; Lianzi Wang; Wei Lv; Shanshan Wang; Dongyue Ma; Yan Zang; Xinyue Zhu; Yuanhong Xu; Lan Zheng; Jilong Shen; Wei Wei
Journal:  Cancer Cell Int       Date:  2022-04-11       Impact factor: 5.722

5.  CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.

Authors:  Ivonne-Aidee Montes-Mojarro; Julia Steinhilber; Christoph M Griessinger; Achim Rau; Ann-Kathrin Gersmann; Ursula Kohlhofer; Petra Fallier-Becker; Huan-Chang Liang; Ute Hofmann; Mathias Haag; Wolfram Klapper; Elke Schaeffeler; Bernd J Pichler; Matthias Schwab; Falko Fend; Irina Bonzheim; Leticia Quintanilla-Martinez
Journal:  Leukemia       Date:  2022-06-08       Impact factor: 12.883

Review 6.  Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.

Authors:  Meng-Yue Shi; Lian Liu; Fu-Yuan Yang
Journal:  World J Stem Cells       Date:  2022-09-26       Impact factor: 5.247

7.  Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab.

Authors:  Alexia Monastirioti; Chara Papadaki; Despoina Kalapanida; Konstantinos Rounis; Kleita Michaelidou; Maria A Papadaki; Dimitrios Mavroudis; Sofia Agelaki
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

Review 8.  Interferon-γ: teammate or opponent in the tumour microenvironment?

Authors:  Angela M Gocher; Creg J Workman; Dario A A Vignali
Journal:  Nat Rev Immunol       Date:  2021-06-21       Impact factor: 53.106

9.  Extracellular vesicles containing miR-146a-5p secreted by bone marrow mesenchymal cells activate hepatocytic progenitors in regenerating rat livers.

Authors:  Norihisa Ichinohe; Masayuki Ishii; Naoki Tanimizu; Toru Mizuguchi; Yusuke Yoshioka; Takahiro Ochiya; Hiromu Suzuki; Toshihiro Mitaka
Journal:  Stem Cell Res Ther       Date:  2021-05-29       Impact factor: 6.832

10.  Epithelial-Mesenchymal Transition Gene Signature Related to Prognostic in Colon Adenocarcinoma.

Authors:  Constantin Busuioc; Cristina Alexandra Ciocan-Cartita; Cornelia Braicu; Oana Zanoaga; Lajos Raduly; Monica Trif; Mihai-Stefan Muresan; Calin Ionescu; Cristina Stefan; Carmen Crivii; Nadim Al Hajjar; Simona Mǎrgǎrit; Ioana Berindan-Neagoe
Journal:  J Pers Med       Date:  2021-05-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.